• If you are wondering whether ImmunityBio's share price still offers value after a strong run, it helps to step back and look carefully at what the market is currently pricing in.
• The stock last closed at US$9.40, with returns of 14.5% over the past week, 8.0% over the past month, 365.3% year to date, 229.8% over one year and negative 61.9% over five years. This gives a mixed picture of recent momentum and longer term experience for shareholders.
• Recent headlines around ImmunityBio have focused on its position in the pharmaceuticals and biotech space as investors weigh up its prospects against the wider sector. This context is important when thinking about how much optimism or caution is already reflected in the current price.
• On Simply Wall St's valuation checks, ImmunityBio scores 2 out of 6. The next step is to compare what different valuation methods say about the stock and, later in the article, look at a broader way to judge whether that price really makes sense.

ImmunityBio scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: ImmunityBio Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today in dollar terms.

For ImmunityBio, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $341.7 million. Analyst estimates and extrapolations used in the model show free cash flow remaining negative in 2026 at about $195.9 million and 2027 at about $48.9 million. It then moves to positive territory with $397.7 million in 2028, $615.6 million in 2029 and $988.96 million in 2030.

Beyond the explicit analyst window, Simply Wall St extrapolates further free cash flow projections out to 2035, all in dollars. Discounting these projected figures back to today produces an estimated intrinsic value of about $36.48 per share.

Against the recent share price of US$9.40, this DCF output suggests the stock is trading at a 74.2% discount to that intrinsic value. Based on these assumptions, the model indicates that the shares appear undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests ImmunityBio is undervalued by 74.2%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.

Approach 2: ImmunityBio Price vs Book

For companies where profits are limited or volatile, the price to book, or P/B, ratio is often a more practical yardstick than earnings based metrics. It links what investors are paying directly to the accounting value of the company’s net assets.

In general, higher growth expectations and lower perceived risk can justify a higher “normal” or “fair” P/B ratio, while slower growth and higher risk tend to support a lower multiple. That context matters when you compare any single number in isolation.

ImmunityBio currently trades on a P/B ratio of about 19.31x. This is well above the Biotechs industry average of around 2.45x and above a peer group average of roughly 15.17x. Simply Wall St’s proprietary “Fair Ratio” framework goes a step further by estimating what P/B multiple might make sense after considering factors such as earnings growth, industry, profit margins, market cap and company specific risks.

This Fair Ratio can give a more tailored reference point than a simple comparison with peers or the broad industry, because it adjusts for the company’s own characteristics rather than assuming all biotechs deserve similar multiples. With no Fair Ratio value provided here, it is not possible to reach a firm view on whether the current 19.31x looks high, low or about right on this basis.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your ImmunityBio Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of ImmunityBio into a clear story that connects the business developments you care about, your own revenue, earnings and margin assumptions, and a Fair Value estimate that you can compare with today’s price. Each Narrative sits inside the Community page and updates automatically as new earnings or news arrive. One investor might build a cautious ImmunityBio Narrative around a Fair Value of US$11.00, while another, using the same company but different assumptions, might land closer to US$23.00, and you can see both side by side before deciding what makes sense for you.

Do you think there's more to the story for ImmunityBio? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.